Clinical trials: Stable Vitiligo
Vitiligo
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
- Trial name
- NCT04547998
- Testing
- Control Intervention (UVB), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
- Where
- 12 sites in United States
- Volunteers
- 25 people
- Sponsor
- Avita Medical
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo.
- Trial name
- Tranquillo 2 (NCT06072183)
- Testing
- Ritlecitinib
- Where
- 229 sites in United States, Australia and 16 more
- Volunteers
- 1,571 people
- Sponsor
- Pfizer
Vitiligo
Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.
- Trial name
- TONE (NCT05971381)
- Testing
- RECELL® Autologous Cell Harvesting Device
- Where
- 17 sites in United States
- Volunteers
- 109 people
- Sponsor
- Avita Medical
Vitiligo
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo.
- Trial name
- Tranquillo LTE (NCT06163326)
- Testing
- Ritlecitinib, Ritlecitinib 100 mg
- Where
- 73 sites in United States, Australia and 11 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Vitiligo, Piebaldism
Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism
The purpose of this study is to assess the efficacy of autologous epidermal cells suspension grafting using a newly developed device named VITICELL® compared to placebo.
- Trial name
- NCT02156427
- Testing
- VITICELL
- Where
- 5 sites in Belgium, France and 1 more
- Volunteers
- 38 people
- Sponsor
- Laboratoires Genévrier
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
- Trial name
- Tranquillo (NCT05583526)
- Testing
- Ritlecitinib
- Where
- 115 sites in United States, Australia and 13 more
- Volunteers
- 607 people
- Sponsor
- Pfizer
Vitiligo
Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions
Prospective randomized within-subject controlled feasibility study to evaluate the clinical performance of RECELL for repigmentation of stable, depigmented lesions.
- Trial name
- NCT04271501
- Testing
- Melanocyte-Keratinocyte Transplantation and Ultraviolet Lamp (UVB), RECELL 1:5 and Ultraviolet Lamp (UVB), RECELL 1:10 and Ultraviolet Lamp (UVB)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Avita Medical
NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable…
- Trial name
- MTII-VIT (NCT07437560)
- Testing
- Melanotan II (MT-II), Narrowband UV-B (NB-UVB) phototherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hudson Biotech